Fibronectin extra domain A (EDA) sustains CD133+/CD44+ subpopulation of colorectal cancer cells

Stem Cell Research

Volumn 11, Issue 2, 2013, Pages 820-833

  Ou, Juanjuan ^a   Deng, Jia ^a   Wei, Xing ^a   Xie, Ganfeng ^a   Zhou, Rongbin ^a   Yu, Liqing ^b   Liang, Houjie ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF MARYLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA9BETA1 INTEGRIN; BETA CATENIN; CD133 ANTIGEN; CELL MARKER; CYTOKERATIN 7; FIBRONECTIN; FIBRONECTIN EXTRA DOMAIN A; FOCAL ADHESION KINASE; HERMES ANTIGEN; INTEGRIN; MITOGEN ACTIVATED PROTEIN KINASE; MUCIN 2; OCTAMER TRANSCRIPTION FACTOR 4; PHOSPHOTRANSFERASE; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2; UNCLASSIFIED DRUG; WNT PROTEIN;

ADULT; ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; CANCER CELL; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER TISSUE; CARCINOGENESIS; CELL SUBPOPULATION; COLON CANCER; COLORECTAL CANCER; CONTROLLED STUDY; EARLY CANCER; EMBRYONIC STEM CELL; FEMALE; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DOMAIN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SPHEROID CELL; TISSUE LEVEL; TUMOR DIFFERENTIATION; TUMOR XENOGRAFT; WNT SIGNALING PATHWAY;

ANTIGENS, CD; ANTIGENS, CD44; CELL CYCLE; CELL DIFFERENTIATION; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; FEMALE; FIBRONECTINS; GLYCOPROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; INTEGRINS; MALE; MIDDLE AGED; PEPTIDES;

EID: 84879577302     PISSN: 18735061     EISSN: 18767753     Source Type: Journal    
DOI: 10.1016/j.scr.2013.05.009     Document Type: Article

References (62)

1. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:3983-3988.
2. Allen M., Louise Jones J. Jekyll and Hyde: the role of the microenvironment on the progression of cancer. J. Pathol. 2010, 223:162-176.
3. Allen M.D., Vaziri R., Green M., Chelala C., Brentnall A.R., Dreger S., Vallath S., Nitch-Smith H., Hayward J., Carpenter R., et al. Clinical and functional significance of alpha9beta1 integrin expression in breast cancer: a novel cell-surface marker of the basal phenotype that promotes tumour cell invasion. J. Pathol. 2011, 223:646-658.
4. Avilion A.A., Nicolis S.K., Pevny L.H., Perez L., Vivian N., Lovell-Badge R. Multipotent cell lineages in early mouse development depend on SOX2 function. Genes Dev. 2003, 17:126-140.
5. Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 1997, 3:730-737.
6. Borsi L., Balza E., Carnemolla B., Sassi F., Castellani P., Berndt A., Kosmehl H., Biro A., Siri A., Orecchia P., et al. Selective targeted delivery of TNFalpha to tumor blood vessels. Blood 2003, 102:4384-4392.
7. Cabodi S., del Pilar Camacho-Leal M., Di Stefano P., Defilippi P. Integrin signalling adaptors: not only figurants in the cancer story. Nat. Rev. Cancer 2010, 10:858-870.
8. Chaffer C.L., Weinberg R.A. A perspective on cancer cell metastasis. Science 2011, 331:1559-1564.
9. Chambers I., Colby D., Robertson M., Nichols J., Lee S., Tweedie S., Smith A. Functional expression cloning of Nanog, a pluripotency sustaining factor in embryonic stem cells. Cell 2003, 113:643-655.
10. Chen Y., Wang Z., Chang P., Xiang L., Pan F., Li J., Jiang J., Zou L., Yang L., Bian Z., et al. The effect of focal adhesion kinase gene silencing on 5-fluorouracil chemosensitivity involves an Akt/NF-kappaB signaling pathway in colorectal carcinomas. Int. J. Cancer 2010, 127:195-206.
11. Choi D., Lee H.W., Hur K.Y., Kim J.J., Park G.S., Jang S.H., Song Y.S., Jang K.S., Paik S.S. Cancer stem cell markers CD133 and CD24 correlate with invasiveness and differentiation in colorectal adenocarcinoma. World J. Gastroenterol. 2009, 15:2258-2264.
12. Clarke M.F., Dick J.E., Dirks P.B., Eaves C.J., Jamieson C.H., Jones D.L., Visvader J., Weissman I.L., Wahl G.M. Cancer stem cells - perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res. 2006, 66:9339-9344.
13. Cox D., Brennan M., Moran N. Integrins as therapeutic targets: lessons and opportunities. Nat. Rev. Drug Discov. 2010, 9:804-820.
14. Dalerba P., Dylla S.J., Park I.K., Liu R., Wang X., Cho R.W., Hoey T., Gurney A., Huang E.H., Simeone D.M., et al. Phenotypic characterization of human colorectal cancer stem cells. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:10158-10163.
15. Desgrosellier J.S., Cheresh D.A. Integrins in cancer: biological implications and therapeutic opportunities. Nat. Rev. Cancer 2010, 10:9-22.
16. ffrench-Constant C. Alternative splicing of fibronectin - many different proteins but few different functions. Exp. Cell Res. 1995, 221:261-271.
17. Fu M., Wang C., Li Z., Sakamaki T., Pestell R.G. Minireview: Cyclin D1: normal and abnormal functions. Endocrinology 2004, 145:5439-5447.
18. Ginestier C., Liu S., Diebel M.E., Korkaya H., Luo M., Brown M., Wicinski J., Cabaud O., Charafe-Jauffret E., Birnbaum D., et al. CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J. Clin. Invest. 2010, 120:485-497.
19. Gradl D., Kuhl M., Wedlich D. The Wnt/Wg signal transducer beta-catenin controls fibronectin expression. Mol. Cell. Biol. 1999, 19:5576-5587.
20. Gupta P.B., Chaffer C.L., Weinberg R.A. Cancer stem cells: mirage or reality?. Nat. Med. 2009, 15:1010-1012.
21. Hall P.E., Lathia J.D., Miller N.G., Caldwell M.A., ffrench-Constant C. Integrins are markers of human neural stem cells. Stem Cells 2006, 24:2078-2084.
22. Hongo K., Tanaka J., Tsuno N.H., Kawai K., Nishikawa T., Shuno Y., Sasaki K., Kaneko M., Hiyoshi M., Sunami E., et al. CD133(-) Cells, Derived From a Single Human Colon Cancer Cell Line, Are More Resistant to 5-Fluorouracil (FU) Than CD133(+) Cells, Dependent on the beta1-Integrin Signaling. J. Surg. Res. 2011, 175:278-288.
23. Horst D., Kriegl L., Engel J., Kirchner T., Jung A. Prognostic significance of the cancer stem cell markers CD133, CD44, and CD166 in colorectal cancer. Cancer Invest. 2009, 27:844-850.
24. Huang X., Molema G., King S., Watkins L., Edgington T.S., Thorpe P.E. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science 1997, 275:547-550.
25. Hynes R.O. Integrins: bidirectional, allosteric signaling machines. Cell 2002, 110:673-687.
26. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics, 2009. CA Cancer J. Clin. 2009, 59:225-249.
27. Kaspar M., Zardi L., Neri D. Fibronectin as target for tumor therapy. Int. J. Cancer 2006, 118:1331-1339.
28. Kelly P.N., Dakic A., Adams J.M., Nutt S.L., Strasser A. Tumor growth need not be driven by rare cancer stem cells. Science 2007, 317:337.
29. Kenny P.A., Lee G.Y., Bissell M.J. Targeting the tumor microenvironment. Front. Biosci. 2007, 12:3468-3474.
30. Kim D., Rath O., Kolch W., Cho K.H. A hidden oncogenic positive feedback loop caused by crosstalk between Wnt and ERK pathways. Oncogene 2007, 26:4571-4579.
31. Kinzler K.W., Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996, 87:159-170.
32. Lapidot T., Sirard C., Vormoor J., Murdoch B., Hoang T., Caceres-Cortes J., Minden M., Paterson B., Caligiuri M.A., Dick J.E. A cell progenitor human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994, 367:645-648.
33. Lathia J.D., Gallagher J., Heddleston J.M., Wang J., Eyler C.E., Macswords J., Wu Q., Vasanji A., McLendon R.E., Hjelmeland A.B., et al. Integrin alpha 6 regulates glioblastoma stem cells. Cell Stem Cell 2010, 6:421-432.
34. Lee S.H., Lee Y.J., Han H.J. Role of hypoxia-induced fibronectin-integrin beta1 expression in embryonic stem cell proliferation and migration: Involvement of PI3K/Akt and FAK. J. Cell. Physiol. 2011, 226:484-493.
35. Li C.Y., Li B.X., Liang Y., Peng R.Q., Ding Y., Xu D.Z., Zhang X., Pan Z.Z., Wan D.S., Zeng Y.X., et al. Higher percentage of CD133+ cells is associated with poor prognosis in colon carcinoma patients with stage IIIB. J. Transl. Med. 2009, 7:56.
36. Li Z., Bao S., Wu Q., Wang H., Eyler C., Sathornsumetee S., Shi Q., Cao Y., Lathia J., McLendon R.E., et al. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 2009, 15:501-513.
37. Logan C.Y., Nusse R. The Wnt signaling pathway in development and disease. Annu. Rev. Cell Dev. Biol. 2004, 20:781-810.
38. Miraglia S., Godfrey W., Yin A.H., Atkins K., Warnke R., Holden J.T., Bray R.A., Waller E.K., Buck D.W. A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood 1997, 90:5013-5021.
39. Nichols J., Zevnik B., Anastassiadis K., Niwa H., Klewe-Nebenius D., Chambers I., Scholer H., Smith A. Formation of pluripotent stem cells in the mammalian embryo depends on the POU transcription factor Oct4. Cell 1998, 95:379-391.
40. O'Brien C.A., Pollett A., Gallinger S., Dick J.E. A human colon cancer cell capable of progenitor tumour growth in immunodeficient mice. Nature 2007, 445:106-110.
41. Ohnishi T., Hiraga S., Izumoto S., Matsumura H., Kanemura Y., Arita N., Hayakawa T. Role of fibronectin-stimulated tumor cell migration in glioma invasion in vivo: clinical significance of fibronectin and fibronectin receptor expressed in human glioma tissues. Clin. Exp. Metastasis 1998, 16:729-741.
42. Ou J.J., Wu F., Liang H.J. Colorectal tumor derived fibronectin alternatively spliced EDA domain exserts lymphangiogenic effect on human lymphatic endothelial cells. Cancer Biol. Ther. 2010, 9:186-191.
43. Ou J., Li J., Pan F., Xie G., Zhou Q., Huang H., Liang H. Endostatin suppresses colorectal tumor-induced lymphangiogenesis by inhibiting expression of fibronectin extra domain A and integrin alpha9. J. Cell. Biochem. 2011, 112:2106-2114.
44. Pang R., Law W.L., Chu A.C., Poon J.T., Lam C.S., Chow A.K., Ng L., Cheung L.W., Lan X.R., Lan H.Y., et al. A subpopulation of CD26+ cancer stem cells with metastatic capacity in human colorectal cancer. Cell Stem Cell 2010, 6:603-615.
45. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 2005, 55:74-108.
46. Patrawala L., Calhoun-Davis T., Schneider-Broussard R., Tang D.G. Hierarchical organization of prostate cancer cells in xenograft tumors: the CD44+ alpha2beta1+ cell population is enriched in tumor-progenitor cells. Cancer Res. 2007, 67:6796-6805.
47. Quintana E., Shackleton M., Sabel M.S., Fullen D.R., Johnson T.M., Morrison S.J. Efficient tumour formation by single human melanoma cells. Nature 2008, 456:593-598.
48. Reya T., Morrison S.J., Clarke M.F., Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature 2001, 414:105-111.
49. Ricci-Vitiani L., Lombardi D.G., Pilozzi E., Biffoni M., Todaro M., Peschle C., De Maria R. Identification and expansion of human colon-cancer-progenitor cells. Nature 2007, 445:111-115.
50. Rybak J.N., Roesli C., Kaspar M., Villa A., Neri D. The extra-domain A of fibronectin is a vascular marker of solid tumors and metastases. Cancer Res. 2007, 67:10948-10957.
51. Sancho E., Batlle E., Clevers H. Signaling pathways in intestinal development and cancer. Annu. Rev. Cell Dev. Biol. 2004, 20:695-723.
52. Santimaria M., Moscatelli G., Viale G.L., Giovannoni L., Neri G., Viti F., Leprini A., Borsi L., Castellani P., Zardi L., et al. Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin. Cancer Res. 2003, 9:571-579.
53. Sauer S., Erba P.A., Petrini M., Menrad A., Giovannoni L., Grana C., Hirsch B., Zardi L., Paganelli G., Mariani G., et al. Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients. Blood 2009, 113:2265-2274.
54. Shin J.H., Bae J.H., Lee A., Jung C.K., Yim H.W., Park J.S., Lee K.Y. CK7, CK20, CDX2 and MUC2 Immunohistochemical staining used to distinguish metastatic colorectal carcinoma involving ovary from primary ovarian mucinous adenocarcinoma. Jpn. J. Clin. Oncol. 2010, 40:208-213.
55. Shinde A.V., Bystroff C., Wang C., Vogelezang M.G., Vincent P.A., Hynes R.O., Van De Water L. Identification of the peptide sequences within the EIIIA (EDA) segment of fibronectin that mediate integrin alpha9beta1-dependent cellular activities. J. Biol. Chem. 2008, 283:2858-2870.
56. Singh S.K., Clarke I.D., Terasaki M., Bonn V.E., Hawkins C., Squire J., Dirks P.B. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003, 63:5821-5828.
57. Singh S.K., Hawkins C., Clarke I.D., Squire J.A., Bayani J., Hide T., Henkelman R.M., Cusimano M.D., Dirks P.B. Identification of human brain tumour progenitor cells. Nature 2004, 432:396-401.
58. Takahashi K., Tanabe K., Ohnuki M., Narita M., Ichisaka T., Tomoda K., Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007, 131:861-872.
59. Vaillant F., Asselin-Labat M.L., Shackleton M., Forrest N.C., Lindeman G.J., Visvader J.E. The mammary progenitor marker CD61/beta3 integrin identifies cancer stem cells in mouse models of mammary tumorigenesis. Cancer Res. 2008, 68:7711-7717.
60. Wang J., Rao S., Chu J., Shen X., Levasseur D.N., Theunissen T.W., Orkin S.H. A protein interaction network for pluripotency of embryonic stem cells. Nature 2006, 444:364-368.
61. Wang Q., Chen Z.G., Du C.Z., Wang H.W., Yan L., Gu J. Cancer stem cell marker CD133+ tumour cells and clinical outcome in rectal cancer. Histopathology 2009, 55:284-293.
62. Yeung T.M., Gandhi S.C., Wilding J.L., Muschel R., Bodmer W.F. Cancer stem cells from colorectal cancer-derived cell lines. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:3722-3727.